ZA200300411B - Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders. - Google Patents

Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders.

Info

Publication number
ZA200300411B
ZA200300411B ZA200300411A ZA200300411A ZA200300411B ZA 200300411 B ZA200300411 B ZA 200300411B ZA 200300411 A ZA200300411 A ZA 200300411A ZA 200300411 A ZA200300411 A ZA 200300411A ZA 200300411 B ZA200300411 B ZA 200300411B
Authority
ZA
South Africa
Prior art keywords
treatment
methods
proliferative disorders
cellular proliferative
recognition
Prior art date
Application number
ZA200300411A
Other languages
English (en)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of ZA200300411B publication Critical patent/ZA200300411B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
ZA200300411A 2000-08-10 2001-07-20 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders. ZA200300411B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/636,597 US6565831B1 (en) 1999-02-24 2000-08-10 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders

Publications (1)

Publication Number Publication Date
ZA200300411B true ZA200300411B (en) 2004-01-26

Family

ID=24552555

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200300411A ZA200300411B (en) 2000-08-10 2001-07-20 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders.

Country Status (15)

Country Link
US (4) US6565831B1 (de)
EP (3) EP2016948A3 (de)
JP (1) JP2004505924A (de)
AR (1) AR029839A1 (de)
AT (1) ATE422358T1 (de)
AU (2) AU2001276218B8 (de)
BR (1) BR0113128A (de)
CA (1) CA2415750C (de)
DE (1) DE60137631D1 (de)
ES (1) ES2317921T3 (de)
IL (2) IL153846A0 (de)
MX (2) MX358055B (de)
NZ (1) NZ523509A (de)
WO (1) WO2002011742A2 (de)
ZA (1) ZA200300411B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
JP4146725B2 (ja) * 2000-11-09 2008-09-10 オンコリティクス バイオテク，インコーポレーテッド 細胞増殖性障害の処置のための方法
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
WO2003011230A2 (en) * 2001-08-03 2003-02-13 Board Of Regents, The University Of Texas System Modified reoviral therapy
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
CA2482826C (en) * 2002-05-10 2011-11-22 Oncolytics Biotech Inc. Sensitization of neoplastic cells to radiation therapy with oncolytic viruses
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
CA2522711A1 (en) * 2003-04-25 2004-11-11 Wellstat Biologics Corporation Treating hepatocellular carcinomas using therapeutic viruses
US20050019308A1 (en) * 2003-07-07 2005-01-27 Oncolytics Biotech Inc. Oncolytic viruses for the treatment of neoplasms having activated PP2A or Rac
JP5015601B2 (ja) * 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
US20050137152A1 (en) * 2003-12-19 2005-06-23 Danny Cheung Reovirus for the prevention of neoplasia
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
CA2617600A1 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
BRPI0707684B1 (pt) * 2006-02-02 2021-10-13 Novartis Ag Uso de 40-o-(2-hidroxietil)-rapamicina para fabricar medicamento para tratar distúrbios mediados pelo complexo de esclerose tuberosa
AU2011205053B2 (en) * 2006-02-02 2013-02-07 Novartis Ag Tuberous Sclerosis treatment
DK1984007T3 (en) * 2006-02-13 2015-12-07 Oncolytics Biotech Inc Application of Low-dose local immunosuppression for amplification of viral oncolytic therapy
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
MX2009009598A (es) 2007-03-12 2009-09-21 Oncolytics Biotech Inc Reovirus que tienen secuencias modificadas.
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
TW200909581A (en) * 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
CN101820892A (zh) * 2007-10-22 2010-09-01 昂科利蒂克斯生物科技公司 增殖性疾病的治疗方案
WO2009135614A2 (en) * 2008-05-09 2009-11-12 Bayer Schering Pharma Aktiengesellschaft Use of a virus regimen for the treatment of diseases
WO2009143610A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
CA2743491C (en) 2008-11-11 2016-10-11 Zelton Dave Sharp Inhibition of mammalian target of rapamycin
CN102448487B (zh) 2009-03-16 2016-03-16 麦克马斯特大学 疫苗接种方法
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
JP6034798B2 (ja) * 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
CN105658790A (zh) 2013-02-21 2016-06-08 东安大略研究所儿童医院有限公司 疫苗组合物
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
EP3068411B1 (de) 2013-11-15 2020-03-18 Oncolytics Biotech Inc. Onkolytische viren und wirksamere krebsbehandlungsschemata
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108983A (en) 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
AU5275290A (en) 1989-04-11 1990-11-05 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
DK0931830T3 (da) 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
US5853716A (en) 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
JP2000511539A (ja) 1996-05-31 2000-09-05 ジェネティック・セラピー・インコーポレイテッド 負の選択マーカーをコード化するポリヌクレオチドを含むｔ細胞による対宿主性移植片病の予防
WO1998008541A1 (en) 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
ATE371372T1 (de) 1997-10-09 2007-09-15 Wellstat Biologics Corp Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
US6406861B1 (en) 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US6464976B1 (en) 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
CA2482826C (en) * 2002-05-10 2011-11-22 Oncolytics Biotech Inc. Sensitization of neoplastic cells to radiation therapy with oncolytic viruses

Also Published As

Publication number Publication date
NZ523509A (en) 2004-11-26
BR0113128A (pt) 2003-07-22
CA2415750C (en) 2006-03-28
AU2001276218B2 (en) 2006-08-03
CA2415750A1 (en) 2002-02-14
US7708987B2 (en) 2010-05-04
EP1309334A2 (de) 2003-05-14
MX358055B (es) 2018-08-03
US7452723B2 (en) 2008-11-18
ES2317921T3 (es) 2009-05-01
WO2002011742A2 (en) 2002-02-14
AR029839A1 (es) 2003-07-16
EP2016948A2 (de) 2009-01-21
ATE422358T1 (de) 2009-02-15
EP1309334B1 (de) 2009-02-11
IL153846A (en) 2010-12-30
DE60137631D1 (de) 2009-03-26
US20060073166A1 (en) 2006-04-06
EP2027866A1 (de) 2009-02-25
WO2002011742A3 (en) 2002-04-18
MXPA03000859A (es) 2004-04-05
IL153846A0 (en) 2003-07-31
JP2004505924A (ja) 2004-02-26
US6565831B1 (en) 2003-05-20
AU2001276218B8 (en) 2006-08-24
AU7621801A (en) 2002-02-18
EP2016948A3 (de) 2009-01-28
US20030215443A1 (en) 2003-11-20
US20080075729A1 (en) 2008-03-27
US7014847B2 (en) 2006-03-21

Similar Documents

Publication Publication Date Title
ZA200300411B (en) Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders.
HK1039752A1 (en) Reovirus for the treatment of cellular proliferative disorders
HK1142833A1 (en) Methods for the treatment of cellular proliferative disorders
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
IL164533A0 (en) Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
AU2001285159A1 (en) Methods for treating endocrine disorders
WO2003082208A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AP2210A (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain.
TR199802676A3 (tr) Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem.
WO2005030144A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
MXPA03000905A (es) Compuestos de poliamina ciclicos como tratamiento contra el cancer.
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
EP1442062A4 (de) Verfahren zur behandlung von karzinomen
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
HK1064261A1 (en) Method for the treatment of tobacco.
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
MXPA03001717A (es) METODO PARA EL TRATAMIENTO DE LA MIGRAnA.
MXPA01001535A (es) Dispositivo para irradiacion untravioleta para el tratamiento de aguas residuales.
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
AP2004003070A0 (en) The method of treating cancer.
EP1689706A4 (de) Alpha, beta-ungesättigte sulfoxide zur behandlung von proliferativen erkrankungen
MXPA03004017A (es) Metodo para el tratamiento de inflamacion.